Novartis to relocate Arnhem operations to Amsterdam, 400 jobs affected

pharmafile | September 19, 2018 | News story | Manufacturing and Production, Research and Development Netherlands, Novartis, amsterdam, pahrma, pharma 

Novartis has announced it is to relocate its operations in Arnhem in the Netherlands to the capital city of Amsterdam, according to Dutch regional public broadcaster Omroep Gelderland, uprooting the site from the base it has occupied since the 1950s.

It has been reported that the reason for the move was due to the high renovation costs of the current building on the Raapopseweg. Around 400 staff currently work at the Arnhem site and all will be affected by the move, with the expectation that they will transfer to the new base of operations.

The company said that the new destination was a “logical choice”, given its close proximity to many clients and suppliers around the capital. The move is scheduled for mid-2019 and coincides with the controversial move of the European Medicines Agency to the city of Amsterdam, following the UK’s decision to leave the European Union which forced the agency to vacate its current base in London.

Jan van Dellen,  Alderman for Economic Affairs and Sport in municipality of Arnhem, lamented the news, saying the departure of a company of Novartis’ stature is never good for the city, while Ron van Gent, Regional Director at Dutch employers’ federation VNO-NCW, remarked: “We regret it very much. Novartis is an important company and it involves a large number of high-quality jobs in the Health cluster of Arnhem-Nijmegen.”

Advertisement

Matt Fellows

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content